The European Medical Agency plans pilot for faster feedback for companies with time-critical drug development
EMA developing faster scientific advice pathway, to enable Biotechs to get faster feedback - pilot in Q1 2027. Include cross reference/ mention of IND Pilot scheme and our article
Reference material: https://insights.citeline.com/pink-sheet/r-and-d/ema-to-test-speedier-scientific-advice-for-focused-drug-development-questions-EEMJDZBGZRAEROUN43FIWTGOPU/
September 2026 saw an announcement from EMA around its plans to develop a faster scientific advice (SA) pathway that could help companies obtain quicker feedback on time-critical questions for their development
What is the current process for EMA feedback?
Guidance and scientific advice can be sought from EMA at any point during drug development. For human medicines, scientific advice or protocol assistance is provided by EMAs Committee for Medicinal Products for Human Use (CHMP) on the recommendation of its Scientific Advice Working Party (SAWP). A developer can seek EMA feedback on questions regarding aspects such as:
- Quality e.g. manufacturing, chemical, pharmaceutical and biological testing
- Nonclinical e.g. toxicological and pharmacological testing to demonstrate safety/efficacy
- Clinical e.g. subjects (patients/healthy volunteers), endpoint selection, biomarker strategy
- Methodology e.g. data analysis, statistical tests, modelling and simulation
- Overall development strategy e.g. safety database, bridging strategy, paediatric development
Although not legally binding, EMA scientific advice can play a critical role in shaping and de-risking global development programs by providing regulatory feedback on a broad range of topics, including quality (CMC), nonclinical, clinical, biostatistical, methodological, paediatric, and regulatory strategy considerations. It is particularly valuable for addressing product-specific questions, novel development approaches, and areas where existing EMA guidance is limited, unclear, or does not fully address the proposed development plan.
When considering the overall timeline associated with obtaining EMA Scientific Advice, including preparation of the meeting request and briefing package, submission and validation, and the subsequent Scientific Advice procedure itself, sponsors may face a process that typically extends over 40 to 70 days, depending on whether written advice alone or a meeting with the Agency is requested. As a result, some drug developers may defer seeking regulatory input until key clinical development milestones are reached, potentially increasing development risk, particularly for innovative therapies or novel technologies. Alternatively, sponsors may experience delays to development timelines while engaging with regulatory authorities to obtain the guidance needed to inform critical program decisions.
How will this change with this new process?
As indicated in the report published 31 Aug 2026, a Focus Group consisting of representatives from industry, SAWP, and EMA was formed to assess the potential for an agile scientific advice pathway designed to support accelerated, time-critical drug development, while ensuring the continued robustness and predictability of the EU regulatory framework. In principle agreement on the need for a more agile scientific advice tool, which will be value tested via a pilot phase to commence 1Q27.
What it likely means in practice
The proposed Agile Scientific Advice (ASA) model is intended for focussed, well-defined scientific questions requiring rapid feedback, possibility in areas of unmet medical need or where accelerated SA could meaningfully impact development decisions. Whilst specific details are scarce right now, ASA may be limited to a small number of questions (e.g. up to three), generally within the same discipline, with developers needing to justify both the medical need and necessity for agility in their case. Complex, precedent-setting or multidisciplinary topics would likely remain within the standard SA framework
Further details of the agile pathway are expected to be presented at the EMA’s next R&D stakeholder platform meeting in November 2026.
Why this Matters
Deciding where to conduct a clinical trial is a critical strategic decision for drug developers, often requiring careful consideration of factors such as regulatory CTA requirements and approval timelines, patient access and recruitment potential, site costs and start-up timelines, and the utility of the resulting data to support future clinical development. Any simplification or improvement in these areas can help reduce the trade-offs that sponsors typically face when selecting study locations. Consequently, initiatives that enhance regulatory efficiency and streamline development processes can play an important role in ensuring that the EU remains an attractive and competitive destination within the global clinical research ecosystem.
Part of a bigger framework for global clinical development acceleration
The proposed Agile Scientific Advice (ASA) model appears to be part of a broader trend among leading regulatory authorities, including the FDA, EMA and MHRA, to facilitate earlier regulatory engagement, apply more risk-proportionate evidence requirements, and ultimately accelerate the development of innovative therapies.
In June 2026, the FDA launched Operation TrialBlazer, a Department of Health and Human Services (HHS)-wide initiative aimed at modernising drug development and the clinical research ecosystem. More recently, the FDA announced its Expedited IND Pilot Program, which is accepting applications through October 2026 and is designed to streamline the transition from preclinical development to first-in-human studies through earlier and more iterative regulatory review.
Collectively, these initiatives reflect a growing regulatory focus on reducing unnecessary burden, improving development efficiency, and shortening clinical trial start-up timelines. Similar efforts are also underway in Europe and the UK, including the EMA's planned ASA pilot and the MHRA's accelerated pathways for selected clinical trials.
For drug developers, keeping pace with this rapidly evolving regulatory landscape can be challenging. Organisations that lack the resources or experience to monitor and leverage emerging opportunities may miss valuable mechanisms for accelerating development, potentially resulting in avoidable delays and increased costs. At Fortrea, our Regulatory Strategy consultants maintain close engagement with the global regulatory environment, enabling us to identify relevant acceleration opportunities and incorporate them into our clients' broader development and regulatory strategies to help optimise timelines and reduce execution risk.